Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6351 to 6400 of 8236 results

  1. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Published
    20 November 2020

  2. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)

    This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.

    COVID-19 rapid guideline
    Last updated
    22 June 2022

  3. COVID-19 rapid guideline: critical care in adults (NG159)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    12 February 2021

  4. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    13 October 2020

  5. Infection control: prevention of healthcare-associated infection in primary and community care (CG2)

    This guidance has been updated and replaced by NICE guideline CG139.    

    Clinical guideline
    Published
    25 June 2003

  6. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)

    This guideline has been updated and replaced by NICE guideline CG137.

    Clinical guideline
    Published
    27 October 2004

  7. Falls: the assessment and prevention of falls in older people (CG21)

    This guideline has been updated and replaced by NICE guideline CG161.

    Clinical guideline
    Published
    24 November 2004

  8. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care (CG22)

    This guideline has been updated and replaced by NICE guideline CG113.

    Clinical guideline
    Published
    6 December 2004

  9. Depression: management of depression in primary and secondary care (CG23)

    This guidance has been updated and replaced by NICE guideline CG90.

    Clinical guideline
    Published
    6 December 2004

  10. Lung cancer: diagnosis and treatment (CG24)

    This guideline has been updated and replaced by NICE guideline CG121.

    Clinical guideline
    Published
    23 February 2005

  11. Violence: short-term management for over 16s in psychiatic and emergency departments (CG25)

    This guideline has been updated and replaced by NICE guideline NG10.

    Clinical guideline
    Published
    23 February 2005

  12. Post-traumatic stress disorder: management (CG26)

    This guidance has been updated and replaced by NICE guideline NG116.

    Clinical guideline
    Published
    23 March 2005

  13. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Evidence summary
    Published
    2 July 2013

  14. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Evidence summary
    Published
    23 July 2013

  15. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    13 October 2015

  16. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    16 September 2014

  17. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    6 November 2014

  18. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Evidence summary
    Published
    2 November 2012

  19. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Evidence summary
    Published
    6 January 2015

  20. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    27 January 2015

  21. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    14 December 2012

  22. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    22 March 2016

  23. Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    30 March 2016

  24. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    10 May 2016

  25. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 February 2015

  26. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2015

  27. Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

    This evidence summary has been updated and replaced by NICE guideline NG81.

    Evidence summary
    Published
    17 March 2015

  28. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    28 April 2015

  29. Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

    This evidence summary has been updated and replaced by NICE guideline NG130.

    Evidence summary
    Published
    16 June 2015

  30. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Evidence summary
    Published
    17 December 2013

  31. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    12 October 2012

  32. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    13 January 2014

  33. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Evidence summary
    Published
    28 January 2014

  34. Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)

    This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]

    Evidence summary
    Published
    4 February 2014

  35. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    11 February 2014

  36. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2014

  37. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Evidence summary
    Published
    11 March 2014

  38. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    18 March 2014

  39. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Evidence summary
    Published
    25 March 2014

  40. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Evidence summary
    Published
    26 March 2014

  41. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Evidence summary
    Published
    2 November 2012

  42. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.  

    Evidence summary
    Published
    14 June 2016

  43. Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)

    This evidence summary was withdrawn in September 2017 as the medicine is no longer available.

    Evidence summary
    Published
    21 June 2016

  44. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

    Evidence summary
    Published
    5 October 2016

  45. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  46. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  47. Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

    This evidence summary has been updated and replaced by NICE guideline NG39.

    Evidence summary
    Published
    16 October 2012

  48. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

    Evidence summary
    Published
    9 April 2013

  49. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Evidence summary
    Published
    15 May 2013

  50. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4)

    This guidance has been updated and replaced by NICE diagnostics guidance 32.

    Diagnostics guidance
    Published
    1 August 2012